Warner Chilcott says Watson seeks generic Loestrin

By Elaine Rigoli

Tampa, Fla., June 23 - Warner Chilcott Co. said it has received a paragraph 4 certification notice from Watson Laboratories, Inc. advising of the filing of an abbreviated New Drug Application for a generic version of Loestrin 24 FE.

Loestrin 24 FE, an oral contraceptive launched by Warner Chilcott in April, is protected by U.S. Patent No. 5,552,394, which expires in 2014.

The company said it is reviewing the details of the letter.

Warner Chilcott is a Fajardo, Puerto Rico-based specialty pharmaceutical company focused on developing and manufacturing branded prescription products in women's health care and dermatology in the United States.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.